Clinical AI platforms increasingly compete on how deeply they integrate with the electronic health record, not simply on the quality of their standalone answers. This comparison sets clear inclusion criteria and is explicit throughout about which capabilities are genuinely live today versus publicly announced but not yet available.
Setting genuine inclusion criteria
A platform earns a place on this list if it offers evidence or clinical-knowledge retrieval, has either current EHR access or a publicly documented integration roadmap, and offers clinician-facing functionality rather than purely administrative or billing-focused capability.
The platforms worth including
AMBOSS AI Mode Clinical Care offers live in-chart search today, with patient-context analysis and structured write-back both publicly announced but still in development, covered in detail elsewhere in this content series.
ClinicalKey AI offers current SMART on FHIR single sign-on and API integration, now paired with Wellsheet's already-validated, already-deployed patient-data aggregation model following Elsevier's June 2026 acquisition, covered in detail elsewhere in this series.
UpToDate Expert AI offers broad, already-mature integrations across EHRs, pharmacy and laboratory systems, alongside stated direct connections with ambient documentation platforms including Abridge, Dragon and Suki.
OpenEvidence offers enterprise, EHR-embedded deployment with Sutter Health, Mount Sinai and, as of May 2026, Cedars-Sinai specifically, reading patient context directly from Epic to support what the company calls agentic clinical intelligence.
DynaMedex and DynaMed Decisions offer their own established evidence-based reference and decision-support model, with integration capability worth checking directly against current specifications.
Heidi Evidence offers evidence retrieval embedded within a live consultation and documentation workflow, a genuinely different integration point from the chart-reading model most of the rest of this list pursues.
iatroX stands as a standalone UK alternative, offering strong national-guidance grounding without current deep EHR integration, a genuine and openly stated trade-off for faster, lower-friction individual clinician access.
Comparing across the dimensions that matter
EHR launch, simply opening the tool from within the record without patient-data use, is now table stakes across most of this list. Patient-data use, genuine reading and reasoning over the record, is live at enterprise scale for OpenEvidence specifically and in development for AMBOSS and ClinicalKey AI. Write-back, sending suggested content directly into the record, remains genuinely rare and tightly governed across the entire category. Local-protocol support, incorporating institution-specific guidance alongside national or international sources, is an emerging rather than established capability across this list. Citation traceability varies in depth and presentation but is present in some form across every platform included here. Drug information is a core, well-established capability across most of these tools. Geographic localisation differs sharply, with most of this list weighted towards US content specifically. And individual versus enterprise access differs substantially, with some platforms, iatroX and AMBOSS's individual-clinician tier among them, remaining directly accessible without institutional procurement, while others depend entirely on a health system's own enterprise contract.
Being explicit about deployment stage
This comparison distinguishes deliberately, for every platform included, between capability available today, capability in pilot or limited deployment, and capability that exists only as a publicly announced roadmap, since conflating these three categories is one of the most common ways this kind of comparison misleads readers.
Giving credit where it is genuinely due
AMBOSS deserves credit for its explicit, publicly stated three-stage architecture, a genuinely more transparent roadmap than many competitors offer. ClinicalKey AI deserves credit for already having both SMART on FHIR integration and, following the Wellsheet acquisition, a validated patient-data model with real hospital deployment behind it. And UpToDate deserves credit for the sheer breadth of its existing enterprise and ambient-platform integrations, built up over a considerably longer operational history than most of its newer competitors.
Where iatroX fits for clinicians who cannot wait for enterprise deployment
iatroX is positioned specifically for clinicians who need accessible UK guidance now, without waiting for their own health system to complete a lengthy enterprise deployment of any of the platforms above.
An evaluation checklist for health-system buyers
Before committing to any platform in this category, a buyer should confirm directly: what is actually live today versus roadmap, what specific patient-data fields are read and how that is governed, what write-back capability exists and what clinician-approval step gates it, how local institutional protocols are incorporated alongside national guidance, and what independent evaluation, beyond the vendor's own reported benchmarks, exists to support any claimed safety or accuracy advantage.